Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) has announced that it recently received the "Chemical API Marketing Authorization Approval Notice" issued by China's National Medical Products Administration for its dexmethylphenidate hydrochloride active pharmaceutical ingredient.

Dexmethylphenidate hydrochloride is a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD).

The receipt of this approval marks a significant regulatory milestone for the company's product pipeline, allowing it to proceed with the commercial production and marketing of this API in the domestic market.